HER-2/neu Protein Expression and Gene Alteration in Stage I-IIIA Non-Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization

Diagnostic Molecular Pathology

Volumn 12, Issue 4, 2003, Pages 201-211

  Tan, Dongfeng ^a,b   Deeb, George ^b   Wang, Jianmin ^a   Slocum, Harry K ^a   Winston, Janet ^a   Wiseman, Sam ^a   Beck, Amy ^a   Sait, Sheila ^a   Anderson, Timothy ^a   Nwogu, Chukwumere ^a   Ramnath, Nithya ^a   Loewen, Gregory ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Fluorescent in situ hybridization (FISH); Gene amplification; HER 2 neu; Non small cell lung cancer; Tissue microarray

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG PARENCHYMA; LUNG SMALL CELL CANCER; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 10744231647     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200312000-00004     Document Type: Article

References (31)

1. Girard L, Zochbauer-Muller S, Virmani AK, et al. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000;60:4894-4906.
2. Saigia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1988;16:1207-1217.
3. Zhu W, Zou H, Beck A, et al. Loss of heterozygosity in primary lung cancer using laser capture microdissection and WAVE DNA fragment analysis techniques. Med Sci Monit. 2002;8:95-99.
4. Gill G, Bertics P, Santon J. Epidermal growth factor and its receptor. Mol Cell Endocrinol. 1987;51:169-186.
5. Parsons JT, Parsons SJ. Protein-tyrosine kinases, oncogenes and cancer. In: DeVita VT, Hellmann S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA: Lipincott-Raven Publishers, 1993;3-18.
6. Pass HI, Mitchell JB, Johnson DH, et al. (eds). Lung Cancer: Principles and Practice. Philadelphia, PA: Lippincott Willliams & Wilkins, 2000.
7. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta. 1994;1198:165-184.
8. Fernandez Val J, Losada J, Arregui Murua M, et al. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. Cancer Gen and Cytogen. 2002;138: 69-72.
9. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep Test in determining the HER-2/neu status of breast cancers using the United States Food and Drug Administration approved scoring system. J Clin Oncol. 1999;17:1983-1987.
10. Swede H, Moysich KB, Freudenheim JL, et al. Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev. 2001;25: 511-519.
11. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 2002;33:105-110.
12. Harpole DH, Marks JR, Richards EG, et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res. 1995;1:659-664.
13. Kern JA, Slebos RJ, Top B, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinoma. J Clin Invest. 1994;93:516-520.
14. Pfeiffer P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small cell lung cancer: An immunohistochemical study on cryosections. Br J Cancer. 1996;74:86-91.
15. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 1999;86:1976-1984.
16. Travis WD, Colby TV, Corrin B, et al. World Health Organization Classification of Lung and Pleural Tumors. Berlin, Germany: Springer-Verlag, 1999.
17. Ramnath N, Hernandez F, Tan DF, et al. Mdm-2 is an independent predictor of survival in non-small-cell lung cancer. J Clin Oncol. 2001;19: 259-266.
18. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4:844-847.
19. Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002;8:540-58.
20. Tan DF, Huberman J, Hyland A, et al. Mcm2IBM8: A novel diagnostic marker for early detection of premalignant squamous epithelial lesions. BMC Cancer. 2001;11:1-6.
21. Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. Anticancer Res. 2000;20:2091-2096.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-81.
23. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34: 187-220.
24. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;86:1449-1456.
25. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer Ed. 5 DeVita V. T. Hellmann S. Rosenberg S. A. eds. Cancer: Principles in Practice of Oncology,: 858-910, Lipincott-Raven Publishers Philadelphia, 1997.
26. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987;235:177-182.
27. Chiang PW, Beer DG, Wie WL, et al. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res. 1999;5:1381-1386.
28. Koka V, Potti A, Koch M, et al. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res. 2002;22:1593-1597.
29. Kristiansen G, Yu Y, Petersen S, et al. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer. 2001;37:1089-1095.
30. Greenlee RT, Hill-Harmon BB, Murray T, et al. Cancer Statistics, 2001. CA Cancer J Clin. 2002;51:16-36.
31. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct omparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Onc. 2000;18:3651-664.